Sign in
4

Changes in Ownership

Beam Therapeutics Inc. Filed Acc 0001193125-26-138348

CEO sold 50,000 shares at an average $22.57 ($1,128,315)

  • CEO acquired 50,000 shares (option exercise)
  • CEO acquired 90,000 shares (grant or award)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Evans John M. CEO 2026-03-30 Option exercise 10b5-1 +25,000 $0.67 $16,750 1,011,667 D: show line 1 in the form
Evans John M. CEO 2026-03-30 Sale 10b5-1 −25,000 $22.37 $559,230 986,667 D: show line 2 in the form
Evans John M. CEO 2026-03-31 Option exercise 10b5-1 +25,000 $0.67 $16,750 1,011,667 D: show line 3 in the form
Evans John M. CEO 2026-03-31 Sale 10b5-1 −25,000 $22.76 $569,085 986,667 D: show line 4 in the form
Evans John M. CEO 2026-03-31 Grant or award 10b5-1 +90,000 1,076,667 D: show line 5 in the form
Open-market sales · 50,000 sh · avg $22.57 · $1,128,315

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Evans John M. CEO 2026-03-30 Option exercise · Stock Option (Right to Buy) 10b5-1 −25,000 43,672 D: show line 6 in the form
Evans John M. CEO 2026-03-31 Option exercise · Stock Option (Right to Buy) 10b5-1 −25,000 18,672 D: show line 7 in the form
Loading xslF345X06/ownership.xml…